Looking forward to participating in this great forum on optimizing cancer vaccines led by Bhardwaj Lab at #AACR24 ! Will discuss neoantigen prediction, evolution & recent updates on work with Vinod BalachandranMD on #mrna vaccines:

abstractsonline.com/pp8/#!/20272/s…

Memorial Sloan Kettering Cancer Center Computational Oncology at Memorial Sloan Kettering

We have just announced 3-year Ph1 follow-up data for our individualized #mRNA cancer vaccine candidate autogene cevumeran (BNT122) showing a persistent immune response and delayed tumor recurrence in some patients with resected #PDAC . #AACR24
Find out more about the results⬇️

Presenting today!

Ballroom 20AB. 3pm start, we will be ~430pm.

Clinical trials mini-symposium on Cancer Vaccines.

Proud to be on this incredible team with Marty Taylor, MD PhD MassGeneral News, Donna Romero ROME Therapeutics, Trevor Van Eeuwen Rout Lab Rockefeller University, Eddy Arnold Rutgers University, Matthias Götte University of Alberta, & Kathleen Helen Burns Dana-Farber & co in nature 👇👇👇

nature.com/articles/s4158…

Fantastic Foundation for the National Institutes of Health awards ceremony to celebrate amazing work. FNIH CEO Julie Gerberding led congratulations to...

Lurie Prize: Vamsi Mootha, Navdeep Chandel

Trailblazer Prize: Vinod BalachandranMD

Charles Sanders Partnership Award: Diana Bianchi (@NICHD_NIH), GSK, O'Neill Family

The FNIH has named Vinod Balachandran, MD, recipient of the 2023 Trailblazer Prize for Clinician-Scientists for his groundbreaking research on new immunotherapies for pancreatic cancer. 

Read the full press release here bit.ly/44nZtvV

Very honored (and surprised!) to receive this.

So lucky to work everyday Memorial Sloan Kettering Cancer Center with exceptionally talented clinicians and scientists determined to crack #PancreaticCancer .

Much progress is needed!

Exciting news! 🔬 After encouraging results from a phase I trial, funded by Lustgarten, a phase 2 clinical trial has now opened to test the effectiveness of using an mRNA vaccine to fight pancreatic cancer @MSKCC #ResearchIsFundamental #ProgressIsParamount lfdn.org/44g13jn

Randomized phase 2 trial of #mRNAvaccines for #pancreaticcancer

NOW OPEN Memorial Sloan Kettering Cancer Center!

More info on enrollment👇🏽
mskcc.org/news/can-mrna-…

What did we find in the phase 1?👇🏽
twitter.com/TheVinodLab/st…

'Should the combination of rationally designed mRNA vaccines and immunotherapy succeed in reproducibly eliciting immune responses that safely and effectively keep cancers in check, it offers potential for broad application,' nature details:go.nature.com/44nCsK1 #CancerResearch

Great time talking #mRNAvaccines for #pancreaticcancer with RNZ Saturday Morning!

In case you missed the tweetorial with more details on the paper, take a look 👇🏽

twitter.com/TheVinodLab/st…

#Personalized #RNA neoantigen #vaccines stimulate #Tcells in #pancreaticcancer : Lustgarten Foundation PanCAN nature.com/articles/s4158…

Congratulations Eileen M O’Reilly for the MJH Life Sciences® #giantsofcancer #2023 #gastrointestinalcancer . Memorial Sloan Kettering Cancer Center MSK Department of Medicine and we are all proud of you! Congratulations

Encouraging early results for personalized mRNA #vaccine plus checkpoint inhibitor in pancreatic cancer: jwat.ch/423bm9C #PancreaticCancer

Congratulations to The V Foundation grantee Dr. Benjamin D. Greenbaum and team Memorial Sloan Kettering Cancer Center who developed the computational strategy used to track the immune response in a personalized mRNA vaccine to pancreatic cancer. nih.gov/news-events/ni… Incredible progress!

Its #TransposonThursday ! Sharing our newest preprint on context dependent mechanisms by which cancer cells co-evolve with retrotransposons (LINE1 and SINEs) to mitigate viral mimicry. A #TeamScience effort led by our postdoc Siyu Sun Computational Oncology at Memorial Sloan Kettering
👇👇👇
biorxiv.org/content/10.110…

For this month’s #JEMjc JExpMed, we would like to highlight the recent phase I trial study by Vinod BalachandranMD, Benjamin D. Greenbaum, Luis A. Rojas, Zachary Sethna Memorial Sloan Kettering Cancer Center on personalized neoantigen #mRNAvaccines for #pancreaticcancer #PDAC .
nature.com/articles/s4158…

Great time discussing #mRNAvaccines for #PancreaticCancer with Today, Explained.

Tweetorial with juicy details on the paper ICYMI is 👇🏽

twitter.com/TheVinodLab/st….

Great time talking #mRNAvaccines and #cancer with Diane Reidy-Lagunes and Dmitriy Zamarin MD PhD!

🧵 on #mRNAvaccines for #pancreaticcancer 👇🏽

twitter.com/TheVinodLab/st…

Podcast 👇🏽

Provoking an immune response in half of the trial patients treated, a pancreatic cancer vaccine marked a development 'in the yearslong movement to make cancer vaccines tailored to the tumors of individual patients,' The New York Times describes. More: nyti.ms/42R9amh #CancerVaccine